News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More INCREDIBLE relevant CBD NEWS FOR CVSI (CV Sciences), but NOT for CVS 😆 🧌
https://www.frontiersin.orghttps//www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1528520/abstract
https://aacrjournals.org/cancerres/article/85/8_Supplement_1/1788/756423/Abstract-1788-Exosomal-formulation-of-cannabidiol
https://aacrjournals.org/cancerres/article/85/8_Supplement_1/1388/756175/Abstract-1388-Exploring-the-apoptosis-inducing
“Trolls will always just be trolls, and not smart educated successful investors.”
💥MORE GREAT BREAKING CBD SECTOR NEWS💥
https://www.marijuanamoment.net/new-federally-backed-marijuana-research-center-launches/
https://pubmed.ncbi.nlm.nih.gov/40219215/
💥More Breaking CBD News💥
💥 https://www.businesswire.com/news/home/20250423877953/en/Cannabis-Edibles-Opportunity-Analysis-Report-2025-Market-to-More-than-Quadruple-to-%2454-Billion-by-2034-Driven-by-Shifting-Consumer-Preferences-Evolving-Regulations-and-Product-Innovations---ResearchAndMarkets.com 💥
https://www.sciencedirect.com/science/article/pii/S2214388225000335
https://dea.lib.unideb.hu/items/0697ea54-62bf-41fb-9ee1-6569f36d4cfa
WQLF SAYS: The WQLFPACK hears another loser crying YQU Understand. It’s berry obvious that the Bashtards have no business savvy. They sure know how to use the yellow pages and walk at the same time YQU Understand. Have Mercy Have Faith Have Patience Have CVSI friendly takeover. WQLF Ahooooooo
Dr. Joong J Fang Said: Nice article on CBD Tommy. CBD sales continuing to grow, except for CV Sciences competition.
Wolfman Jack Said; We hear you knocking but you can’t come in wet loser you Understand. Have Mercy Ahooooooo
MORE GREAT BREAKING CBD RESEARCH
https://www.sciencedirect.com/science/article/abs/pii/S1526590025006054
https://www.neurology.org/doi/10.1212/WNL.0000000000208686
WQLF SAYS: YQU were WISE to Quit posting on the BS Yahoo Forum. Unfortunately, they have come to post on this board with their disinformation and childish bashing. Chrissy poo 💩 is posting disinformation that the annual meeting voting includes a Reverse Split. This is far from the Truth. The WQKIMON is using TWO alias’s on this board as well. Glad we are staying with three board members. It cuts costs and allows room for the deep pocket company that will be acquiring us in the near future to place their board members. Have Mercy Have Faith Have Patience WQLF Ahooooooo
WQLF COMPARISON ANALYSIS
This is what GREAT MANAGEMENT ACCOMPLISHES YQU NOW UNDERSTAND YQU UNDERSTAND. Have Mercy WQLF Ahooooooo to the Ahloloooosers
WINNER 🏆 🏅 🏆 & STILL WINNING
CV SCIENCES
Financial Highlights
Fiscal Year
Fiscal Year Ends 12/31/2024
Most Recent Quarter (mrq) 12/31/2024
Profitability
Profit Margin -15.24%
Operating Margin (ttm) -10.38%
Management Effectiveness
Return on Assets (ttm) -8.57%
Return on Equity (ttm) -101.92%
Income Statement
Revenue (ttm) 15.71M
Revenue Per Share (ttm) 0.09
Gross Profit (ttm) 7.17M
EBITDA -840k
Net Income Avi to Common (ttm) -2.39M
👇👇👇👇👇👇👇👇👇👇
Diluted EPS (ttm) -0.0100
Quarterly Earnings Growth (yoy) --
CBDmd
Financial Highlights
Fiscal Year
Fiscal Year Ends 9/30/2024
Most Recent Quarter (mrq) 12/31/2024
Profitability
Profit Margin -13.99%
Operating Margin (ttm) -1.69%
Management Effectiveness
Return on Assets (ttm) -10.96%
Return on Equity (ttm) -60.98%
Income Statement
Revenue (ttm) 19.22M
Revenue Per Share (ttm) 4.08
Quarterly Revenue Growth (yoy) -4.90%
Gross Profit (ttm) 11.84M
EBITDA -1.17M
Net Income Avi to Common (ttm) -6.69M
👇👇👇👇👇👇👇👇
Diluted EPS (ttm) -1.3400
CHARLOTTES WEB
Financial Highlights
Fiscal Year
Fiscal Year Ends 12/31/2024
Most Recent Quarter (mrq) 12/31/2024
Profitability
Profit Margin -60.09%
Operating Margin (ttm) -43.05%
Management Effectiveness
Return on Assets (ttm) -15.03%
Return on Equity (ttm) -72.23%
Income Statement
Revenue (ttm) 49.67M
Revenue Per Share (ttm) 0.31
Quarterly Revenue Growth (yoy) -20.10%
Gross Profit (ttm) 21.26M
EBITDA -22.01M
Net Income Avi to Common (ttm) -29.85M
👇👇👇👇👇👇👇👇👇
Diluted EPS (ttm) -0.1900
💥 ANOTHER RETAILER ALREADY SELLING LUNAR FOX 🦊 FOODS PRODUCTS 💥
Country Village Nutrition Shoppe
https://scontent-iad3-1.xx.fbcdn.net/v/t39.30808-6/491815991_1227927462671044_4022022296541628061_n.jpg?_nc_cat=101&ccb=1-7&_nc_sid=833d8c&_nc_ohc=w4sNkmaBpNMQ7kNvwGXx3wq&_nc_oc=Adn60ck9ZnE4stIAv1ebDf3TncCSqrTQig7p5jx4x7ITVBCV4r4t7wRbXdGvsi50_vdRieFwxwDi3Ak4gkv7SYLw&_nc_zt=23&_nc_ht=scontent-iad3-1.xx&_nc_gid=n44uPujLAmfPI_5nkhDmOw&oh=00_AfGztBcCS8MBG4qAiZFZ9v44LVgakEFEDEIoC33NWU6CDw&oe=680C16E4
https://ir.cvsciences.com/press-releases/detail/234/cv-sciences-unveils-lunar-fox-food-co-an-all-new-line-of
https://www.lunarfoxfoods.com/
https://veggs.eu/
https://culturedfoods.eu/
https://ir.cvsciences.com/press-releases/detail/219/cv-sciences-inc-acquires-cultured-foods-to-enter
https://onlinelibrary.wiley.com/doi/10.1002/jnr.70035
WQLF SAYS; Because they are doing a GR8 job. If one had cost averaged down instead of just holding their $6.00 CVSI shares from 2019 they would understand YQU NOW Understand YQU understand. One should be thankful that there has been no dilution except for understandable reasons such as, Acquisitions, Employees, Directors, Bartering, Etc. Also NO Reverse Splits, Law Suits, and NO long term debt, only short term debt that keeps the company solvent and repaid within a years time. Have Mercy Have Faith Have Patience WQLF Ahooooooo
Wolfman Jack Said; Happiness is having close to two million shares and a break even at $.11 cents a share You Understand Ahooooooo Being sad and depressed is holding 100 CVSI shares with a cost average of $6.00 per share YOU DO Understand YOU Understand. Have Mercy Ahooololoooo
A Wolf Song for the WQKE Shareholder LOSERS;
💥GREAT NEWS FOR CV SCIENCES, +PlusCBD, Lunar Fox 🦊/ Cultured Foods and Elevated Softgels 💥
https://www.supplysidesj.com/supplement-regulations/industry-insiders-describe-potential-impacts-of-rfk-jr-marty-makary-on-fda-dietary-supplements
https://www.supplysidesj.com/supplement-regulations/novel-ingredients-take-focus-in-supplement-sector
https://www.supplysidesj.com/supplements/dietary-supplement-industry-cheers-rfk-jr-s-hhs-nomination
https://ir.cvsciences.com/press-releases/detail/219/cv-sciences-inc-acquires-cultured-foods-to-enter
https://www.globenewswire.com/news-release/2025/01/20/3011956/28124/en/United-States-Plant-Based-Food-Market-Forecasts-Report-2025-2033-Major-Food-Corporations-Expand-Offerings-Amid-Growing-Demand-Celebrity-Endorsements-and-Media-Influence-QSRs-Domina.html
https://fooddigital.com/food/plant-based-food-market-set-for-substantial-growth-by-2031
https://culturedfoods.eu/
https://ir.cvsciences.com/press-releases/detail/234/cv-sciences-unveils-lunar-fox-food-co-an-all-new-line-of
https://www.lunarfoxfoods.com/
https://veggs.eu/
https://ir.cvsciences.com/press-releases/detail/228/cv-sciences-launches-plushlth-a-new-line-of
https://ir.cvsciences.com/press-releases/detail/221/cv-sciences-inc-expands-pluscbd-pet-product-offerings
https://ir.cvsciences.com/press-releases/detail/224/cv-sciences-inc-acquires-elevated-softgels-a-flexible
https://maho4health.org/trade-show/exhibitor-list-2025/
✅ https://www.maximgrp.com/home
WQLF SAYS: GR8 News for CV Sciences and CBD Sector
https://www.fiercepharma.com/pharma/fda-blocks-biopharma-employees-serving-advisory-committees
💥More Great Breaking CBD news.💥
https://www.degruyterbrill.com/document/doi/10.1515/tnsci-2022-0362/html
https://www.neurology.org/doi/10.1212/WNL.0000000000210898
💥MORE GREAT BREAKING NEWS💥
https://www.marijuanamoment.net/cbd-helped-relieve-chronic-pain-in-more-than-98-of-patients-newly-published-study-finds/
https://www.marijuanamoment.net/largest-ever-analysis-of-medical-marijuana-to-treat-cancer-symptoms-shows-overwhelming-scientific-consensus-on-benefits/
https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/draft-report
https://www.mdpi.com/1422-0067/26/7/3428
💥BOOM💥, LUNAR FOX 🦊 FOODS EXPANDING RAPIDLY 💥
Here’s more locations, besides what I’ve already mentioned!
https://www.facebook.com/share/p/1EMWaVUxfY/
https://ir.cvsciences.com/press-releases/detail/234/cv-sciences-unveils-lunar-fox-food-co-an-all-new-line-of
https://www.lunarfoxfoods.com/
https://ir.cvsciences.com/press-releases/detail/219/cv-sciences-inc-acquires-cultured-foods-to-enter
Hey Mutt and Jeff let's try and make some sales to make this com;pany profitable. Otherwise get off the grass and get real!!!! Ahoooooooooooooooooo To you))))))))))))))))). Your bulll only goes so far!!!!!!!!!! Time to get real!!!!! RealahOOOOOOOOOOOOOOOOOO!!!!
WQLF SAYS; Sir Thomas, I believe that the company entered into the latest agreement with the lender in order to pay Extract Labs the $400,000 offering for the acquisition. Extract Labs sent a letter to CV Sciences on February 5, 2025. The lending agreement was finalized on February 12, 2025. I imagine the company was borrowing enough to get through a certain time frame. Maybe the $400,000 was going to be replaced by the additional revenue from the acquisition. Now we have the monies in hand. I am glad the acquisition fell through. $1,000,000 in shares at around.03 per share is a good bit of Dilution not including the earnout.Around 33,333,333 shares. Hopefully we can do another acquisition just to extract and formulate gummy’s and not have to bother with a company selling similar and competitive products that CV Sciences offers. The only thing the Extract Labs acquisition had to offer besides the extraction and manufacturing along with the distribution is the Delta 8 and the Vapors. Two product lines that are in dispute with the regulators.
In consideration for the Acquisition, at closing, the Company (i) will make a cash payment of $400,000 to the Sellers, less a $20,000 holdback (the “Holdback Amount”), less certain assumed indebtedness and less certain transaction expenses, subject to certain other adjustments provided for in the Purchase Agreement (the “Closing Payment”), and (ii) will issue to the Sellers a number of shares of the Company's common stock with an aggregate value equal to $1,000,000 less certain assumed indebtedness, based on the trailing 60 day volume weighted average price (“VWAP”) of such common stock as of the trading day prior to the closing date (the “Closing Shares”) . The Closing Payment will be subject to adjustment, upward or downward, to the extent Extract Labs’ net working capital as of the closing is greater than or less than $880,000. Additionally, the Company shall be entitled to recover from the Sellers an amount equal to the unpaid balance of all accounts receivable that were included in the Extract Labs final working capital statement, to the extent they remain uncollected 90 days after the determination of the final working capital statement.
In addition to the consideration payable at closing, and as further consideration for the Acquisition, the Sellers shall be entitled to receive up to two additional earnout payments payable in shares of restricted common stock of the Company (the “Earnout Amount”). The Earnout Amounts shall be based on Extract Labs’ Net Revenue (as defined in the Purchase Agreement) generated during the 12-month period following the closing date (for the first calculation period) or 24-month period following the closing date (for the second calculation period) and will be calculated as follows:
•
If Extract Labs’ Net Revenue is at least $4,600,000 in the relevant calculation period, then the Earnout Amount for such period will be $300,000.
•
If Extract Labs’ Net Revenue is at least $4,300,000 but less than $4,600,000 in the relevant calculation period, then the Earnout Amount for such period will be $200,000.
•
If Extract Labs’ Net Revenue is at least $4,000,000 but less than $4,300,000 in the relevant calculation period, then the Earnout Amount for such period will be $100,000.
•
If Extract Labs’ Net Revenue is at least $3,500,000 but less than $4,000,000 in the relevant calculation period, then the Earnout Amount for such period will be $50,000.
•
If Extract Labs’ Net Revenue is less than $3,500,000 in the relevant calculation period, then the Earnout Amount for such period will be $0.”
Item 1.01 Entry into a Material Definitive Agreement
“On February 12, 2025, CV Sciences, Inc., a Delaware corporation (the “Company”) entered into a Note Purchase Agreement (“Purchase Agreement”) with an institutional investor (“Investor”), pursuant to which the Company issued and sold to the Investor a Secured Promissory Note in the original principal amount of $1,600,000 (the “Note”). The Note carries an original issuance discount of $400,000 which was deducted from the proceeds of the Note received by the Company which resulted in a purchase price received by the Company of $1,200,000 (the “Purchase Price”). In addition, the Company agreed to pay $10,000 to the Investor to cover its legal fees.”
CJ Montgomery
COO Elevated Softgels- Full Time
https://ir.cvsciences.com/press-releases/detail/224/cv-sciences-inc-acquires-elevated-softgels-a-flexible
https://elevatedsoftgels.com/
Lead executive of custom softgel and tincture manufacturing facility serving the nutritional supplement and hemp industry.
Our hands-on expertise in botanical and cannabinoid blends allows our facility to provide R&D, formulation, and production services to clients worldwide.
President: https://mirthprovisions.com/
Manufacturer of legal cannabis beverages for the l-502 licensed retail market.
Owner: https://www.speedwinds.com/about.html
Founder: https://www.cbdpure.com/about-us/
Number of shares of CV Sciences Common Stock Beneficially Owned 15,854,185 (8.6%)
Lets hope idiot Dowling acquires something profitable because he sure has run this company into the ground with zero profits!!!!
Have Mercy Have Faith Have Patience Have Domestic and International Partners and MORE Profitable Acquisitions. WQLF Ahooooooo
Ahooooooo back to youoooooooo
WQLF SAYS; Gr8 diligence and promotion of CV Sciences CEO Joseph Dowling for for your WQKIMON Team player to fret over YQU Understand. To give one some common sense knowledge about interviews, one has to understand the Interviewer. In the Gr8 interview YQU promoted on the CVSI were Questions about the CBD industry in general and Joseph Dowling’s knowledge was very much right on the mark. He certainly knew his market of the industry back in 2021, and his expertise and knowledge about the future of the CBD industry was spot on. Here is an interview that you could have added to your repertoire that does bring out the salesman ship of Joseph Dowling. I call it Questions 67 and 68 YQU Now Understand YQU Understand. Have Mercy Have Faith Have Patience Have Domestic and International Partners and MORE Profitable Acquisitions. WQLF Ahooooooo This interview starts out about CVSI but you if listen to it, Dowling never refers back to CVSI products. He just promotes CBD in general instead of plugging CVSI products!!!!! Sales is CVSI's problem and Dowling doesn't help by not continuing to refer to CVSI products!!!!! Typical scientist brain or accounting brain certainly not a salesman.
WQKIMON JUNIOR SAID;
JOSEPH DOWLING SAID;
WQLF SAYS; Follow up to the WQKIMON Question about the PAST EXPERIENCES of the CEO of CV Sciences Joseph Dowling. Here is a startup company he was involved with when it was formed in 2012. It is still a growing and striving corporation that is a Global Business organization thanks to his leadership and experience in making startups successful as he has done with CV Sciences.
“Digitech Solutions, Inc.: Digitech Solutions, Inc. is an electronics company located in Los Angeles, California. The company focuses on providing services and solutions tailored for designers, emphasizing creativity, style, and ideas. They offer home automation services, which include advanced systems to enhance the functionality and convenience of smart homes. Their commitment to designers is reflected in their mission to support and empower creative professionals.
The company can be reached through their email at info @Tamulonis. They are active on social media platforms such as Facebook, Twitter, and Instagram, where they share updates and engage with their community.
Reviews and ratings for Digitech Solutions, Inc. are not provided in the available context, but the company's focus on designer-centric services and home automation suggests a strong emphasis on innovation and customer satisfaction. If you are a designer or interested in home automation, Digitech Solutions, Inc. may be a valuable resource for your needs.“
http://digitechsolutions.com/
Who we are;
“Built on 12 years of reputation and experience, Digitech Solutions can offer telecommunication solutions to any type of organisation.
Digitech can offer you and your company, services including Special Rate Service Numbers, Premium Rate Service Numbers, Carrier Pre-Select, Tailor made Call Plans and now we are able to bring to you SMS services.
We can offer you ready-made SMS products that enable you to generate revenue immediately. In addition to this we are constantly releasing new products to our SMS range every week and many of these are exclusive to Digitech Solutions.
The future of Your Call Centre Options are Just a Phone Call Away.”
Digitech Solutions Global Limited, The Business Centre, 1 Finway Luton LU1 1TR
http://digitechsolutions.com/aboutUs.html
NEXT ⬆️ UP
“ About MediVas
Using its proprietary family of biodegradable and biocompatible polymers, MediVas has developed unique platforms for the delivery of biologics. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical companies, as well as on its own internal product development efforts, to create groundbreaking medical advancements.
By combining therapeutic proteins and other biologics with a MediVas polymer, delivery routes that were previously unattainable, such as oral, intranasal, inhaled or subcutaneous injection, can now be achieved. With these routes of delivery then available, MediVas' delivery system can make the administration of the biologic more convenient, more efficacious and safer, leading to higher patient compliance and overall better health.”
https://www.bionity.com/en/companies/22706/medivas-llc.html
DSM obtains exclusive world-wide license for MediVas' drug delivery technology
13-Mar-2009 - Netherlands
Royal DSM N.V announced that DSM Biomedical obtained an exclusive world-wide license for a unique drug & biologics delivery system developed by MediVas LLC. Integrated into DSM's Trancerta® drug delivery platform, this will open up a broad range of opportunities for next generation drug delivery. DSM's activities in this field are an illustration of the way DSM is leveraging its competences in Materials Sciences into Life Sciences applications.
MediVas' technology for the delivery of biologics and drugs is based on a next generation set of polymers exclusively licensed from Cornell University. Generated from research both at Cornell and at MediVas, the company has an IP portfolio containing over 60 issued or pending patents. The polymers are biodegradable, biocompatible and bioabsorbable. Furthermore they are non-inflammatory and allow greater control over the rate and duration of release of their therapeutic payload.
The technology can be used with a diverse group of drug candidates, from small molecule drugs to large molecules like proteins, peptides and nucleic acids, thus expanding the possible application areas of DSM's Trancerta® platform. The license DSM obtained applies for the development of drug delivery systems aimed at treating ophthalmic, (cardio)vascular, musculoskeletal diseases and at providing general pain relief.
"Through this deal we bring in the first fully developed biodegradable polymer into DSM's Biomedical portfolio, which significantly enhances our materials competences. This will help us realize our ambition to build a portfolio of drug delivery technologies tailored at the specific needs of the health industry. MediVas' technology is already proven in two clinical studies which should allow us to accelerate the commercialization of our drug delivery technologies in partnerships with Pharma, Biotech and Medical Device companies," said Steve Hartig, President of DSM Biomedical.
WQLF SAYS: Joseph Dowling is the perfect candidate to take this company to higher levels due to his commitment and dedication to making CV Sciences one of the leaders in the Wellness Industry through product development and innovation and marketing initiatives needed for a sustainable future in the CBD industry. Thank YQU for the opportunity to join us today and in the near future for the company’s success through the leadership of CV Sciences team of experts in the Wellness sector through successful innovations and collaboration with Partners and Acquisitions. Have Mercy Have Faith Have Patience Have International and Domestic Partnerships. YQU Now Understand YQU Understand. WQLF Ahooooooo Anyone have an opinion on this CEO's performance? How did he do at the company prior to this?
WQKIMON SAID ;
Dr. Joong J Fang Said: Here is the successful past experience of the Man with the Plan.
Joseph Dowling Work History
Joseph Dowling, the Chief Executive Officer of CV Sciences, previously served as the company's Chief Financial Officer from June 16, 2014, to May 31, 2018. Before joining CV Sciences, he held various finance and accounting roles in both public accounting and the banking industry. He also worked in the biotech and finance industries, holding executive positions at companies such as Digitech Solutions and MediVas, LLC. Additionally, he provided strategic consulting, restructuring, and corporate finance services at firms like Coopers & Lybrand and KPMG.
Wolfman Jack Said; ONE DAY We’ll ALL Understand You Understand. Have Mercy Ahooooooo
WQLF SAYS : When the reciprocal tariffs on Canada take affect, how much more will Lunar 🦊 Fox prosper? Have Mercy Have Faith Have Patience Have International Partners WQLF Ahooooooo
https://tsdr.uspto.gov/#caseNumber=98388857&caseSearchType=US_APPLICATION&caseType=DEFAULT&searchType=statusSearch
https://www.plantbasedfoodscanada.ca/
https://www.plantbasedfoodscanada.ca/members
Make American Healthy Again (MAHA)
https://maho4health.org/
https://maho4health.org/about-us/board-of-directors/ (Our NEW Nationwide Distribution Partner: Palko Services.)
https://maho4health.org/trade-show/exhibitor-list-2025/
+ PlusCBD by CV Sciences and Palko Serrvices
https://www.maha.vote/
https://www.cvsciences.com/
https://ir.cvsciences.com/board-of-directors
https://www.maximgrp.com/home
WQLF SAYS; Thank YQU MAHA Tariffs. Have Mercy Have Faith Have International Partners WQLF Ahooooooo
https://timesofsandiego.com/tech/2025/04/11/swiss-novartis-to-open-san-diego-research-hub/
💥Positive changes happening now to quickly weed out the bad actors!
https://www.marijuanamoment.net/florida-senate-passes-bill-to-restrict-hemp-products-like-delta-8-thc/?
https://www.marijuanamoment.net/missouri-bill-to-regulate-intoxicating-hemp-products-stalls-in-senate-following-7-hour-filibuster/
https://www.marijuanamoment.net/indiana-bill-to-regulate-hemp-derived-delta-8-thc-products-heads-to-house-floor-vote/
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0320756
💥BOOM💥 BREAKING NEWS SHOULD BE COMING SOON…💥
https://mailchi.mp/hempsupporter/today-witness-history-during-first-congressional-hearing-on-hemp-cbd-and-fda-inaction-5333867?e=1163a68b22
💥 https://www.marijuanamoment.net/watch-live-hemp-industry-expert-testifies-before-congressional-committee-on-fda-inaction-around-cbd-and-intoxicating-cannabinoid-products/
“One potential legislative solution that Miller said he planned to raise with the committee at the hearing is a bipartisan bill Sen. Ron Wyden (D-OR) filed last year that would create a federal regulatory framework for hemp-derived cannabinoids.”
“The legislation would empower states to set their own rules for products such as CBD while also empowering FDA to ensure that certain safety standards are met in the marketplace.”
https://link.greenmarketreport.com/view/6601cf108d1d2209bd877600nfrna.1q6/9f0e7a48
https://www.marijuanamoment.net/watch-live-hemp-industry-expert-testifies-before-congressional-committee-on-fda-inaction-around-cbd-and-intoxicating-cannabinoid-products/
https://www.marijuanamoment.net/alabama-lawmakers-approve-bill-directing-alcohol-regulators-to-oversee-consumable-hemp-products/
+PlusCBD Aspirin coming soon…. ?
https://journals.lww.com/co-neurology/fulltext/9900/cannabinoids_in_headache__helpful_or_harmful_.235.aspx
💥TODAY:
https://mailchi.mp/hempsupporter/today-witness-history-during-first-congressional-hearing-on-hemp-cbd-and-fda-inaction-5333837?e=1163a68b22
💥Member: CV SCIENCES
Happening Tomorrow! U.S. Hemp Roundtable General Counsel, Jonathan Miller, to Testify Before House Oversight Committee.
https://mailchi.mp/hempsupporter/today-witness-history-during-first-congressional-hearing-on-hemp-cbd-and-fda-inaction-5333837?e=1163a68b22
Member: CV Sciences
https://hempsupporter.com/about/
💥 Reminder and Follow-UP ⬆️ isTOMORROW 💥
To my attached post.
https://docs.house.gov/Committee/Calendar/ByEvent.aspx?EventID=118131
WQLF SAYS: It’s about time, between RC Cola and Gotliberal, and the Big Pharma bed they slept in, change is finally on the horizon YQU now Understand YQU Understand. Have Mercy Have Faith Have Patience and BUY BUY BUY E. F. WQLF Ahooooooo
“ While the current FDA Commissioner, Martin A. Makary has not yet issued new public remarks on CBD, the agency’s long-held position was reiterated last year by his predecessor, Robert Califf, during a March 2024 hearing.”
What a Dork
“ He was a paid consultant for Merck Sharp & Dohme, Johnson & Johnson, GlaxoSmithKline, AstraZeneca, and Eli Lilly per ProPublica from 2009 to 2013. The largest consulting payment was $87,500 by Johnson & Johnson in 2012, and "most of funds for travel or consulting under $5,000", which has been called "minimal for a physician of his stature".[14] From 2013 to 2014 he was paid a total of $52,796; the greatest amount being $6,450 from Merck Sharp & Dohme, followed by Amgen, F. Hoffmann-La Roche AG, Janssen Pharmaceutica, Daiichi Sankyo, Sanofi-Aventis, Bristol-Myers Squibb and AstraZeneca.”
https://en.m.wikipedia.org/wiki/Robert_Califf
PETERFFY: I THINK THIS IS THE GREATEST BUYING OPPORTUNITY I’VE SEEN.
💥 HEARING WEDNESDAY ON A BIPARTISAN BILL SEN. RON WYDEN (D-OR) FILED LAST YEAR THAT WOULD “CREATE A FEDERAL REGULATORY FRAMEWORK FOR HEMP- DERIVED CANNABINOIDS”.💥
https://www.marijuanamoment.net/congressional-committee-invites-hemp-industry-expert-to-testify-at-hearing-on-how-fda-failed-to-regulate-products/
U.S. HEMP ROUNDTABLE MEMBER: CV SCIENCES
https://hempsupporter.com/about/
https://www.mdpi.com/1999-4923/17/3/328
|
Followers
|
568
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
83926
|
|
Created
|
02/27/13
|
Type
|
Free
|
| Moderators Zorax Wolf-man jack Thomas@yahoo | |||
Acquisition: CV Sciences, Inc. (OTCQB:CVSI) has entered into a definitive agreement to acquire Extract Labs, Inc., a manufacturer and distributor of premium cannabinoid products, including gummies, topicals, and tinctures. The acquisition is valued at $400,000 in cash and $1,000,000 in CV Sciences’ common stock, with potential additional shares based on revenue targets.
Extract Labs’ Operations: Extract Labs has operational flexibility, allowing for low to large minimum order quantity production runs, enabling efficient use of capital and increased speed to market for new product development. The company is GMP-certified and FDA-registered.
Post-Acquisition Plans: CV Sciences plans to increase Extract Labs’ existing revenue base and further leverage its existing capacity. Additionally, CV Sciences intends to in-source the manufacturing of select +PlusCBD™ branded products, providing an opportunity for meaningful cost savings.
Financial Considerations: The total consideration for the acquisition payable at closing consists of a cash payment of $400,000, less certain holdbacks and adjustments, and the issuance of shares of CV Sciences’ common stock valued at $1,000,000 based on the 60-day volume-weighted average price of CV Sciences’ common stock. Extract Labs sellers will be eligible for up to $600,000 of additional shares if certain revenue targets are met during the two 12-month periods following the closing date.
Business Overview: CV Sciences is a consumer wellness company specializing in nutraceuticals and plant-based foods, with a focus on hemp extracts and other proven, science-backed ingredients and products. The company’s +PlusCBD™ branded products are sold through various channels, including retail locations and online.
Extract Labs’ Products: The company offers a range of products, including gummies, topicals, and tinctures, which are sold through business-to-business (B2B) and business-to-consumer (B2C) channels.
Quality and Testing: CV Sciences has high standards for quality, purity, and potency of its CBD products, with third-party lab testing to ensure the absence of pesticides, fungicides, plant growth regulators, residual solvents, heavy metals, and microbiological contamination.
CV Sciences, Inc., a consumer wellness company specializing in hemp extracts and other proven science-backed, natural ingredients and products, acquired Elevated Softgels, a leading manufacturer of encapsulated softgels and tinctures for the supplement and nutrition industry, in May 2024.
Elevated Softgels manufactures a range of products, including:
Elevated Softgels’ large-scale softgel manufacturing setup allows for:
The acquisition of Elevated Softgels by CV Sciences enhances the company’s product offerings, manufacturing capabilities, and scalability, positioning it for long-term growth and success in the consumer wellness industry.
AI
